News
Thu, 01 May 2025 06:32:00 -0400
Thu, 01 May 2025 06:32:00 -0400
PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS Caremark, the country's largest Pharmacy Benefit Manager (PBM) has decided that Wegovy® (semaglutide) injection 2.4 mg, the most widely prescribed and studied GLP-1 for weight loss, will soon be the preferred GLP-1 medicine on its largest commercial template formularies. This change will be effective July 1, 2025.
"We believe in the unique benefits of Wegovy® and the difference this medicine can make for patients seeking treatment," said Dave Moore, Executive Vice President, US Operations and President of Novo Nordisk Inc. "As the leader in obesity care for more than a decade, it is our responsibility to continue to work with others across the US healthcare system to find innovative opportunities to meet the needs of these patients and connect them with authentic, FDA-approved Wegovy® in a convenient and affordable way."
Independent of this formulary decision, Novo Nordisk will continue to work with CVS to identify additional ways to expand access to Wegovy® for its customers.
Novo Nordisk is building on our efforts to date and will explore all potential avenues that can help patients get the authentic, FDA-approved Wegovy® they need at an affordable cost. In February, all doses of Wegovy® were confirmed to be available by the FDA. In March, Novo Nordisk launched NovoCare® Pharmacy to provide direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for self-paying patients. More recently, the Wegovy® savings offer was updated so that eligible self-paying patients can also get the $499-per-month price at their local pharmacy.
First approved in 2021, Wegovy® is the only FDA-approved semaglutide treatment for weight loss and the medicine that changed how healthcare professionals (HCPs) treat people with obesity as the first weekly GLP-1 option for chronic weight management. Adding to the mounting reasons why HCPs choose Wegovy®, the FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. Wegovy® and the semaglutide molecule continue to be studied across a variety of chronic conditions.
About Wegovy® (semaglutide) injection 2.4 mg
What is Wegovy®?
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Important Safety Information
What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including:
Do not use Wegovy® if:
Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at https://www.novo-pi.com/wegovy.pdf
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
Media: | |
Liz Skrbkova (US) | Ambre James-Brown (Global) |
Investors: | |
Frederik Taylor Pitter (US) +1 609 613 0568 | Jacob Martin Wiborg Rode (Global) |
Sina Meyer (Global) +45 3079 6656 | Ida Schaap Melvold (Global) +45 3077 5649 |
Max Ung (Global) |
SOURCE Novo Nordisk Inc.